Summary
定义
病史和体格检查
关键诊断因素
- male sex
- history of inflammatory bowel disease
其他诊断因素
- age 25-45 years
- abdominal pain
- pruritus
- fatigue
- weight loss
- fever
- jaundice
- steatorrhea
- splenomegaly
- ascites
- encephalopathy
危险因素
- male sex
- inflammatory bowel disease (IBD)
- genetic predisposition
诊断性检查
首要检查
- serum alkaline phosphatase
- serum gamma-GT
- serum aminotransferases (aspartate aminotransferase, alanine aminotransferase)
- serum total bilirubin
- serum albumin
- CBC
- prothrombin time
- abdominal ultrasound
- magnetic resonance cholangiopancreatography (MRCP)
- serum IgG4
需考虑的检查
- endoscopic retrograde cholangiopancreatography (ERCP)
- serum IgM
- antinuclear antibody
- anti-smooth muscle antibody
- antimitochondrial antibody
- abdominal CT scan
- liver biopsy
- bone mineral density scan
- colonoscopy
- imaging-based noninvasive tests for fibrosis
治疗流程
early disease
end-stage liver disease
撰稿人
作者
S. Ian Gan, MD, FRCPC
Associate Clinical Professor
Vancouver General Hospital
University of British Columbia
Vancouver
BC
利益声明
SIG declares that he has no competing interests.
Nawaf Tareq Aboalfaraj, MBBS, FRCPC
Advanced Therapeutic Endoscopy Fellow
McGill University
Montreal
QC
利益声明
NTA declares that he has no competing interests.
鸣谢
Dr S. Ian Gan and Dr Nawaf Tareq Aboalfaraj would like to gratefully acknowledge Dr Kris V. Kowdley and Dr Christine Schlenker, the previous contributors to this topic.
利益声明
KVK is a member of the speakers bureau of Axcan Pharma, manufacturer of Urso250 and Urso Forte, and gives one or two lectures a year on treatment of cholestatic liver diseases. KVK has also received funding from the NIH for a research study of Urso in PSC. CS declares that she has no competing interests.
同行评议者
LIsa Forman, MD
Professor of Medicine
University of Colorado
Aurora
CO
利益声明
LF declares that she has no competing interests.
James Neuberger, BM, BCh
Consultant Physician
Liver Unit
Queen Elizabeth Hospital
Birmingham
UK
利益声明
JN declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
参考文献
关键文献
European Association for the Study of the Liver. EASL clinical practice guidelines on sclerosing cholangitis. J Hepatol. 2022 Sep;77(3):761-806.全文 摘要
Bowlus CL, Arrivé L, Bergquist A, et al. AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2023 Feb 1;77(2):659-702.全文
Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010 Feb;51(2):660-78.全文 摘要
参考文献
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

鉴别诊断
- Secondary sclerosing cholangitis
- Immunoglobulin G4 cholangitis
- Autoimmune hepatitis
更多 鉴别诊断Guidelines
- EASL clinical practice guidelines on liver transplantation
- ACR Appropriateness Criteria: abnormal liver function tests
更多 指南Calculators
MELDNa scores (for liver transplantation listing purposes, not appropriate for patients under age 12 years)
More CalculatorsLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer